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High variability in the dosing of commonly used
antibiotics revealed by a Europe-wide point
prevalence study: implications for research and
dissemination
Tuuli Metsvaht1,2*, Georgi Nellis1,3, Heili Varendi3, Anthony J Nunn4, Susan Graham5, Andre Rieutord6, Thomas Storme7,
James McElnay8, Hussain Mulla9, Mark A Turner10 and Irja Lutsar1
Abstract
Background: Antibiotic dosing in neonates varies between countries and centres, suggesting suboptimal
exposures for some neonates. We aimed to describe variations and factors influencing the variability in the dosing
of frequently used antibiotics in European NICUs to help define strategies for improvement.
Methods: A sub-analysis of the European Study of Neonatal Exposure to Excipients point prevalence study was
undertaken. Demographic data of neonates receiving any antibiotic on the study day within one of three two-week
periods from January to June 2012, the dose, dosing interval and route of administration of each prescription were
recorded. The British National Formulary for Children (BNFC) and Neofax were used as reference sources. Risk factors
for deviations exceeding ±25% of the relevant BNFC dosage recommendation were identified by multivariate logistic
regression analysis.
Results: In 89 NICUs from 21 countries, 586 antibiotic prescriptions for 342 infants were reported. The twelve
most frequently used antibiotics – gentamicin, penicillin G, ampicillin, vancomycin, amikacin, cefotaxime,
ceftazidime, meropenem, amoxicillin, metronidazole, teicoplanin and flucloxacillin – covered 92% of systemic
prescriptions. Glycopeptide class, GA <32 weeks, 5th minute Apgar score <5 and geographical region were
associated with deviation from the BNFC dosage recommendation. While the doses of penicillins exceeded
recommendations, antibiotics with safety concerns followed (gentamicin) or were dosed below (vancomycin)
recommendations.
Conclusions: The current lack of compliance with existing dosing recommendations for neonates needs to be
overcome through the conduct of well-designed clinical trials with a limited number of antibiotics to define
pharmacokinetics/pharmacodynamics, efficacy and safety in this population and by efficient dissemination of the
results.
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Background
Recent data suggest that, depending on NICU level, up
to 20–40% of admitted neonates receive antibiotic ther-
apy on any particular day, with 30–90% of them exposed
to at least one antibiotic during their admission [1-4].
The vast majority of antibiotics are used off-label; data
on dosing in this patient group are limited or are gener-
ally based on expert opinion or small studies not includ-
ing all gestational age (GA) groups [2-5]. While some
questionnaire-based studies of neonatal antibiotic doses
suggest compliance with existing dosing recommenda-
tions, others, including unpublished data from the Anti-
microbial Resistance and Prescribing in European
Children (ARPEC) point prevalence study (PPS), have
highlighted large variations in dosing regimens of many
commonly used antibiotics in neonates [6-8]. Although
therapeutic indications may significantly affect dosing in
older children, such variation is not generally expected
in neonates. Unexplained dosing variability is a marker
of suboptimal patient management meaning that some
babies are under- while others are over-dosed. This
raises a number of questions about how to deliver opti-
mal dosage of antibiotics to neonates. Is more research
needed, or should efforts to disseminate existing evi-
dence be improved?
Extant data do not provide a basis to identify which ac-
tions are needed to overcome variability. Previous research
efforts to understand which doses of antibiotics are used
in neonates have focused on agents with a narrow thera-
peutic window and/or unfavourable side effect profile or
extreme lack of neonatal data, like vancomycin, flucona-
zole or ciprofloxacin [6,8,9]. Two approaches have been
applied, i.e. questionnaire-based studies of policy about
dosing regimens and safety data retrieval from the litera-
ture [8-13]. Such studies do not allow estimation of actual
drug use distribution and are prone to underestimation of
variability, as dosing regimens that have been used are not
recorded.
In order to improve this situation it is important to
understand the causes of the variation. We aimed first,
to collect and document details regarding the dosing of
antibiotics in European neonatal units and second, to
determine whether there are systematic influences on
doses which could be the target for interventions to ra-
tionalise prescribing.
Methods
A sub-analysis of the multicentre single day PPS of the
European Study of neonatal Exposure to Excipients
(ESNEE), detailed elsewhere, was performed [14,15]. The
study included 27 European Union countries plus Iceland,
Norway, Switzerland and Serbia. General neonatal, inter-
mediate and NICU as well as mixed paediatric and
neonatal intensive care units with more than 50% of ad-
missions consisting of neonates were eligible.
For current analysis, all prescriptions for systemic antibi-
otics in neonates up to 90 days of age, active on the study
day morning, chosen by the unit within one of three fixed
two-week study periods from January to February; March
or May to June, 2012, were retrieved from the ESNEE PPS
database. Topical antibiotics, antivirals and antifungals
were excluded. Anonymised demographic data including
gender, gestational age (GA), birth weight (BW), 1 and 5
minute Apgar score, current body weight (CBW) and
postnatal age (PNA) were recorded for each neonate. Post-
menstrual age was calculated based on GA and PNA. Due
to differences in the pharmacokinetics of antibiotics be-
tween term and preterm neonates, but also fast changes
occurring over the first weeks of life, dosing recommenda-
tions for this age group are based not only on body weight
but also GA and/ or PMA. In the dosing analysis further
grouping by PMA or PNA was based on the recommen-
dations for the respective antibiotic in the chosen dosing
references (Tables 1, 2). Prescription data included active
ingredient, route of administration and individual dosing
regimen (unit dose and dosing interval) together with pre-
scription start date.
Because most Summary Product Characteristics (SPC)
lack neonatal dosing recommendations [2], the Manual
of Childhood Infections (the Blue Book 2010), the British
National Formulary for Children (BNFC) 2010–2011
[16,17] and Neofax 2010, 23rd edition [18] were chosen as
the guidance documents of drug dosing in neonates, i.e.
current editions at the start of the study. BNFC, although
country specific by origin, has gained Europe-wide ac-
ceptance, as one of the few dosing references, which
brings together authoritative, independent guidance on
best practice and clinically validated drug information,
including that on neonates [2]. The Blue Book and
BNFC showed only minimal variations in dosing rec-
ommendations. Therefore, apart from the differences,
highlighted separately, for the sake of clarity and space
data referring to the BNFC is in the focus of results.
For uniformity, in dose deviation assessment all prescrip-
tions were translated into CBW adjusted daily doses. The
lowest unit dose for the respective PNA or postmenstrual
age (PMA) group as appropriate with the longest interval,
including once daily (extended interval) dosing regimen
for aminoglycosides, recommended in BNFC, was used as
the reference (zero line).
Statistical analysis
Statistical software R (version 2.15.1; © 2012 The R
Foundation for Statistical Computing) and Microsoft Excel
(version 14.0.7106.5003; © 2010, Microsoft Corporation)
were used for analysis. Descriptive statistics are presented
as mean and standard deviation (SD) or median and
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quartiles (IQR) as appropriate. In order to assess influ-
ences on prescribing practice, demographic parameters,
European region and antibiotic class were investigated for
associated risk of deviation from the BNFC daily dose rec-
ommendation using univariate logistic regression analysis.
A conservative ±25% deviation was accepted to allow for
possible dose rounding, except in the case of beta-lactams.
For beta-lactam antibiotics the upper limit was set at
+125%, as for severe infections and meningitis doubling
the dose is recommended and indication of the antibiotic
therapy was not collected in the study. Risk factors signifi-
cant at p < 0.1 in univariate analysis were entered into
multiple regression analysis with step-wise removal of the
least significant parameters.
The study was approved by the Ethics Committee of the
University of Tartu; approval in participating countries
was obtained in compliance with national guidelines. The
list of ethics committees that approved the study is pro-
vided in additional material [See Additional file 1]. None
of the ethics committees requested informed consent from
parents as all collected data were anonymised and there
was no interference with management of patients.
Results
Of the 31 invited European countries 21 with 89 NICUs
in 73 hospitals participated in the study (Figure 1)
[14,19]. Intermediate and 3rd level intensive care units
predominated in all participating countries [15]. The
median number of neonates reported per country was
45 (quartile range 26.5–65). A total of 2608 prescriptions
were reported for 1382 patients, with a mean (SD) BW
of 2060 (1032) g and GA of 33 (5) weeks. Among them
342 (25%) patients with mean (SD) BW of 2239 (1075) g
and GA of 34 (5) weeks received 586 antibiotic prescrip-
tions (22% of all prescriptions). A full list of antibiotics
prescribed to neonates is provided in additional material
[see Additional file 2]. The proportion of neonates re-
ceiving systemic antibiotics by country ranged from 4%
to 78% with a median of 26%. The median number of
antibiotic prescriptions per patient was 2 (range 1–5).
There were 573 (98%) parenteral and 13 (2%) enteral
prescriptions. Three neonates were older than 90 days
PNA and were excluded from further analysis.
Most frequently used antibiotics
A total of 37 different systemic antibiotics were prescribed.
Twelve most frequently used active pharmaceutical ingre-
dients – gentamicin, penicillin G, ampicillin, vancomycin,
amikacin, cefotaxime, ceftazidime, meropenem, amoxicil-
lin, metronidazole, teicoplanin and flucloxacillin – covered
538, i.e. 92% of the antibiotic prescriptions. Penicillins
and aminoglycosides were by far the most frequently
prescribed antibiotic classes in all regions, responsible
for 212 (36%) and 178 (30%) of 586 prescriptions,
Table 1 The dosing of frequently used beta-lactam antibiotics in European NICUs
Drug PNA group No of cases Unit dose (mg/kg/dose) Dosing interval (h)
Current study;
median
(quartiles)
Current
study;
range
BNFC/Blue book Neofax Current study;
median
(quartiles)
BNFC/the
Blue book
Neofax
Penicillin G 0–7 days 62 47 (27–53) 10–147 25 (50)*# 15–30 (45–60)* 12 (12–12) 12 12
N = 88 8–28 days 21 33 (31–50) 25–61 25 (50)*# 15–30 (45–60)* 12 (12–12) 8 8–12
>28 days 5 40 (30–43) 28–43 25 (50)*# 15–30 (45–60)* 12 (10–12) 6 (4) 6–8
Ampicillin 0–7 days 69 52 (50–78) 24–126 30 (60; max 62.5)* 25–50 12 (12–12) 12 12
N = 82 8–21 days 6 52 (49–96) 47–96 30 (60; max 62.5)* 25–50 8 (8–12) 8 8–12
22–28 days 4 47 (37–86) 34–99 30 (60; max 62.5)* 25–50 12 (8–12) 6 8–12
>28 days 3 48 (45–69) 45–69 62.5 25–50 12 (8–12) 6 6–8
Cefotaxime 0–7 days 16 46 (29–51) 10–54 25 (50)* 50 12 (12–12) 12 12
N = 32 8–21 days 12 48 (25–50) 13–53 25 (50)* 50 8 (8–12) 8 8–12
>21 days 4 47 (16–49) 5–49 25 (50)* 50 8 (8–8) 6–8 8–12
Ceftazidime 0–7 days 6 30 (25–41) 22–53 25 (50)*& 30 12 (8–12) 24 12
N = 20 8–21 days 5 43 (32–47) 27–49 25 (50)* 30 12 (8–12) 12 8–12
>21 days 9 36 (30–39) 24–47 30 8 (8–12) 8 8–12
Meropenem 0–7 days 10 20 (19–22) 9–39 20 (40)* 20–40* 12 (8–12) 12 12
N = 20 8–28 days 10 21 (15–30) 9–43 20 (40)* 20–40* 10 (8–12) 8 8–12
* – the dose in parentheses is recommended for severe infections and/or meningitis.
# – for meningitis 75 mg/kg recommended in the Blue Book.
& – only the higher dose of 50 mg/kg recommended by the Blue Book.
PNA – postnatal age; BNFC – British National Formulary for Children.
The number of prescriptions with accurate dosing data available is shown for each antibiotic. Data are shown as median and quartiles.
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Table 2 The dosing of frequently used aminoglycosides and glycopeptides in European NICUs
Drug PMA group No of cases Median unit
dose (quartiles;
mg/kg/dose)
Unit dose range
(mg/kg/dose)
Median dosing
interval (quartiles; h)
BNFC/the Blue
book unit dose
(mg/kg/dose)
BNFC/the Blue
book dose
interval (h)
Neofax unit dose
(mg/kg/dose)
Neofax dose
interval (h)c
Gentamicin <32 weeks 21 4.6 (4.2–5.0) 3.3–6.6 36 (24–36); 24–48 4–5 (2.5a) 36 (18–24a) 4–5 36 (24–48)
N = 139 ≥32 weeks 118 4.4 (3.9–4.8) 1.2–19.4 24 (24–24); 12–36 4–5 (2.5a) 24 (12–18a) 4 24 (24–36)
Amikacine PNA 0–28 days 34 15.1 (8.8–17.4) 3.1–18.5 24 (24–36); 12–48 15 (7.5a) 24 (12) 15–18 24–48
N = 35 PNA >28 days 1 7.5 12 15 (7.5a) 24 (12) 15 24
Vancomycinb <29 weeks 5 9.5 9.0–10.0 21 (11–24); 8–24 15 24 10 (15d) 12–18
N = 40 29–35 weeks 14 10.0 (9.3–14.3) 4.8–15.6 15 (12–24); 2–48 15 12 10 (15d) 8–12
>35 weeks 21 11.2 (9.7–14.7) 9.0–18.9 12 (8–12); 8–24 15 8 10 (15d) 6–12
PMA – postmenstrual age; PNA – postnatal age.
a – multiple daily dosing recommendation regimen is given in parenthesis; for gentamicin multiple daily dosing regimen recommendations are for PMA limits <29 weeks; 29–35 weeks and >35 weeks and have been
adjusted accordingly.
b – 9 infants received vancomycin continuous infusion and are excluded from this analysis.
c – different PMA/ PNA groups are applied compared to BNFC, the interval range includes all applicable in the respective PMA/PNA range.
d – meningitis dose.
e – please note, that in contrast to gentamicin and vancomycin dosing based on PMA, current amikacin dosing recommendation is based on PNA.
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respectively. While ampicillin and penicillin G were pre-
scribed at equal frequency in West-European NICUs; in
North-European NICUs penicillin G (OR 11.9; 95% CI
5.8–24.4 compared to East- and South-European NICUs)
and in East - and South -European NICUs ampicillin (OR
4.3; 95% CI 2.4–7.8 compared to North- and West-
Europe) predominated. Gentamicin with 139 prescriptions
(78% of all aminoglycoside prescriptions) was the most
frequently used aminoglycoside, followed by amikacin.
Glycopeptides were prescribed more often in West- and
South- compared to North- and East- (OR 2.3; 95% CI
1.4–4.0) and carbapenems in South- and East- compared
to North- and West- European NICUs (OR 4.4; 95% CI
1.6–12.1).
Accurate information on the start of prescription were
available for 560/586 (96%) of the antibiotic prescrip-
tions. Overall 347 (62%) prescriptions were started
within the first three days of life, including over 80% of
ampicillin, penicillin G and gentamicin prescriptions.
Cefotaxime, amikacin and meropenem had 70% of pre-
scriptions started by the end of the first week of life. In
contrast the cumulative number of ceftazidime and
vancomycin prescriptions increased steadily over the
first month of life. The cumulative proportion of pre-
scriptions for eight most frequently used antibiotic pre-
scriptions by post-natal age is provided in additional
material [see Additional file 3].
Dosing regimen of antibiotics
Antibiotics with 20 or more prescriptions were selected
for detailed analysis (n = 8). Deviations of more than
300% of the recommended daily dose were assumed to
be erroneous and were excluded. Dosing regimen ana-
lysis included 412 prescriptions for five beta-lactam anti-
biotics (penicillin G, ampicillin, cefotaxime, ceftazidime
and meropenem), two aminoglycosides (gentamicin and
amikacin) and vancomycin. The median doses as com-
pared to BNFC 2010–2011 Ed [17] and NeoFax (23rd
Edition, 2010) [18] recommendations by drug class and
PNA/PMA band as appropriate, are shown in Table 1
(beta-lactams) and Table 2 (aminoglycosides and vanco-
mycin). Lower doses of penicillin G and ampicillin and
higher doses of cefotaxime were recommended by Neofax
compared to BNFC.
Figure 1 Participating countries by European region (shown in different shades of blue). Number of NICUs participating from each country is
shown in parentheses.
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For penicillin G the median unit dose was close to the
BNFC recommendation for severe infections in the
youngest and to that of the Neofax in older PNA bands
(Table 1). Ampicillin median unit doses were at the high
end of the Neofax reference in all PNA bands. No reduc-
tion in dosing interval with increasing PNA was seen.
The median dose for cefotaxime equaled the BNFC ref-
erence for meningitis and severe infections. The dosing
intervals, similar in both cited references, were followed
with the only exception of BNFC recommendation of 24 h
for ceftazidime during the first week of life. Meropenem
median dose was equal to the routine recommendation,
dosing intervals in the PNA > 7 days group exceeding the
BNFC but in line with the Neofax reference.
For gentamicin and vancomycin different PMA groups
with generally similar unit doses for gentamicin and
higher doses of vancomycin in the BNFC, were suggested
(Table 2). Amikacin dosing recommendations were based
on PNA group. Gentamicin median unit doses were
within the reference range but in 34 cases (24%) dosing in-
tervals exceeded the longest recommended (once daily
regimen). The BNFC recommended multiple daily dosing
interval was used in 7 (33%) and 12 (10%) neonates in
the <32 weeks and ≥32 weeks PMA group, respectively.
Vancomycin unit doses remained below the reference
range in three quarters of cases with shorter than recom-
mended intervals used in only a quarter of cases.
Variability of daily doses
Deviations from the BNFC reference daily dose for non-
severe infections are depicted in Figure 2 and Figure 3
for beta-lactams and in Figure 4 for gentamicin and
vancomycin. In general, penicillins were given at higher
doses than recommended for non-severe infections. The
highest recommendation for severe infections like menin-
gitis, osteomyelitis and endocarditis (calculated as +125%
of routine dose) was exceeded in 26/82 (32%) of ampicillin
cases and 10/69 (14%) of those involving penicillin G.
For cefotaxime 18/30 (60%) prescriptions were within
the ±25% of the highest recommended dose. Ceftazidime
doses exceeded the maximum for severe infections during
the first 7 days but not thereafter (Figure 3). Daily doses
remained below the reference dose in only 12% of beta-
lactam prescriptions, most frequently for meropenem
(6/20; 30%), followed by cefotaxime (3/30; 10%). The
Figure 2 Variation in the dosing (mg/kg/day) of penicillin G (panel A) and ampicillin (panel B) in comparison to British National Formulary for
Children 2010–2011 recommendations. The minimum accepted unit dose (mg/kg/dose) and dosing interval for the respective PNA group was
used for the calculation of the reference daily dose (zero line). Maximum BNFC recommended daily dose is shown in light grey line. Dotted
coloured lines depict minimum and maximum Neofax 2010 dosing recommendation. Each dot represents a different patient.
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lowest doses of penicillins were in line with the Neofax
recommendation (dotted lines on Figure 2).
Gentamicin daily doses were above or below the ±25%
range of the lowest daily recommendation in 13 (62%)
and 21 (18%) cases in the <32 weeks and ≥32 weeks
PMA groups, respectively. Higher than recommended
daily dosing was the result of shorter intervals rather
than higher unit doses. For vancomycin the majority of
doses (40/48; 83%) remained below the BNFC lowest
reference independent of the PMA group and variability
was highest at <36 weeks of PMA.
In univariate logistic regression analysis BW ≤1500 g;
GA ≤32 weeks, PMA <29 weeks; 1st minute Apgar
score ≤3; 5th minute Apgar score ≤7, treatment in West-
European NICU and glycopeptide class prescription were
associated with higher risk of deviation from the BNFC
recommended dose. On the other hand any beta-lactam,
cephalosporin or aminoglycoside prescription and treat-
ment in North-European NICU had a lower risk of dose
deviation (data not shown).
The results of multivariable logistic regression analysis
are presented in Table 3. Glycopeptide class prescription
was the strongest risk factor of major dose deviation,
followed by treatment in West-European NICU, 5th minute
Apgar score <5 and gestational age <32 weeks. Treatment
in a North-European NICU was the only factor independ-
ently associated with a lower likelihood of major deviations
from BNFC dosing recommendation.
Discussion
In a Europe-wide study looking at the antibiotic dosing
in neonates at the individual level, we have demon-
strated extremely wide and non-random variations in
dosing of the most frequently used antibiotics. In gen-
eral, antibiotics known to be well tolerated (e.g. penicil-
lins and cephalosporins) were given in higher doses than
the reference range. Those with safety concerns were
given in line with (e.g. gentamicin), or at lower than the
reference doses (e.g. vancomycin). Deviations from refer-
ence values tended to be greater during the first 7 days
of life for beta-lactams and in less mature babies (PMA
< 32/36 weeks) for gentamicin and vancomycin, com-
pared to other PNA/PMA groups. Although antibiotics
are by far the most commonly used medicines in neo-
nates [2,3] more than 90% of the prescriptions in our
study included only 12 different antibiotics suggesting
that defining appropriate dosing recommendation for a
relatively small number of agents would resolve the issue
of inappropriate/inadequate dosing for most hospitalised
neonates in Europe.
The reasons for the high variability in dosing of antibi-
otics in neonates are likely multiple. First, high quality data
relevant to dose selection is lacking for many antibiotics
used in neonates [20]. Current guidelines are based mainly
on expert opinion and small studies rather than on well
conducted clinical trials, leading to wide inter-centre vari-
ability in dosing recommendations [2,21,22]. In a recent
study of 56 French NICUs 444 dosing regimens were re-
ported for 41 antibiotics [22]. Uncertainty about the
Figure 4 Variation in the dosing of gentamicin and vancomycin
(mg/kg/day) in comparison to British National Formulary for Children
2010–2011 recommendations. The minimum accepted unit dose
(mg/kg/dose) and dosing interval for the respective PNA group was
used for the calculation of the reference daily dose for all drugs
(zero line). For gentamicin the once daily (extended interval) dosing
regimen was applied.
Table 3 Risk factors of AB dose deviation; multiple
regression analysis
Risk factor OR 95% CI
Glycopeptide prescription 6.9 3.1–15.4
West-Europe 2.2 1.04–4.6
5th minute Apgar score <8 1.8 1.1–3.0
GA <32weeks 1.7 1.02–2.8
North-Europe 0.6 0.3–0.99
Figure 3 Variation in the dosing (mg/kg/day) of cefotaxime,
ceftazidime and meropenem in comparison to British National
Formulary for Children 2010–2011 recommendations. The
minimum accepted unit dose (mg/kg/dose) and dosing interval
for the respective PNA group was used for the calculation of the
reference daily dose (zero line).
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dosing and safety as well as need for additional studies of
efficacy were among the most frequently mentioned factors
influencing decisions in a Europe-wide study of antifungal
prophylaxis in neonates [13]. Safety concerns as a basis for
dosing variations are well reflected by the different pattern
seen for antibiotics with wide vs narrow therapeutic win-
dow in our study. Similarly, a recent study looking at dos-
ing of antifungals (generally associated with poor tolerance
and unfavourable side effect profile) in European children,
found under-dosing in about half of the cases [23].
Additional difficulties are posed by changes in the PK
of antibiotics over the first few weeks of life, a factor that
requires appropriate dose adjustments [24]. The best
compliance with existing dose recommendations was
seen for drugs like cephalosporins and meropenem, with
more recent, adequate PK data resulting in similar dose
recommendations in both reviewed references [25-30].
In contrast, the PNA-specific rule in the BNFC for ceftazi-
dime (once daily dosing over the first week of life followed
by twice daily thereafter) was not followed, despite clear
evidence from PK studies [31].
Other reasons of the high variability in dosing include
problems in adoption and dissemination of evidence
based knowledge.The former is reflected by penicillin G
dosing recommendations contradicting recent PK stud-
ies [32-34]. Evidence of poor dissemination of changing
recommendations and the relative conservatism of the
clinical community is provided by the examples of ami-
noglycosides and vancomycin. The once daily or ex-
tended interval dosing of aminoglycosides, supported by
PK and clinical studies including safety assessment in
neonates [35-37], appears to be not yet completely ac-
cepted after two decades of intense debate. Multiple daily
dosing with less than a 24h interval was used in 14% of
cases in our study. Vancomycin was associated with the
highest likelihood of major dose deviations, reflecting diffi-
culties in adopting more recent and probably more contro-
versial dosing recommendations of an agent known to
have significant side effects [38]. There is clearly a need for
improved dissemination of evidence-based guidelines in
European neonatal units via professional societies or regu-
latory initiatives, where appropriate.
Clinicians can adapt to well-founded guidelines that are
adequately disseminated. In our study this is reflected by
differences between European regions. Western Europe,
likely relying on dosing references other than the BNFC
alone, was associated with the highest likelihood of devi-
ation from the BNFC reference. In contrast, Northern
Europe, predominately represented by UK NICUs, had the
best compliance with BNFC recommendations.
The main limitation of the study is the lack of data on
the indications for which antibiotics were prescribed.
The majority of antibiotics are prescribed to neonates
for suspected rather than proven infection [39]. In our
study about 2/3 of antibiotics were prescribed within the
first three days of life. Only 3–8% of such neonates have
been found to develop proven sepsis [39-41]. Infections
like meningitis, osteomyelitis or endocarditis requiring
specific dosing of beta-lactam antibiotics, are extremely
rare in neonates [17,18,39]. The reported incidences
range from 0.21 and 0.12 per 1000 live births for menin-
gitis and osteomyelitis, respectively [42,43] to 0.7 per
1000 Special Care Nursery admissions in the case of
endocarditis [44,45]. Therefore, the wide dosing varia-
tions seen in our study cannot be explained by treatment
indications. Furthermore, accepting the dose recom-
mended for severe infections in all cases, as done in our
analysis, reflects the most conservative approach. BNFC
was used as the dosing reference in this analysis, while
other sources may have been used in some centres.
However, this fact does not undermine our main finding
of the high variability in the dosing of most frequently
used antibiotics in neonates. Neither clinical studies nor
epidemiological data provide any rational explanation. In
addition, therapeutic drug monitoring (TDM) data may
have affected vancomycin and aminoglycoside dosing
in the study. Even assuming TDM results to be the
underlying reason for all dose deviations supports our
thesis that the precision/value of current dosing recom-
mendations needs to be or is being questioned by clini-
cians. As the data were collected in a large multi-national
setting with no data monitoring and queries applied, ex-
treme deviations were excluded from analysis.
Conclusions
In conclusion, the prescribing practice of antibiotics in
European neonatal units is highly variable but is not
random. There are some systematic influences on dose
being selected. These influences stem from demo-
graphic and geographic variables and from the class of
antibiotics used. Clinicians’ and experts’ distrust of
newer dosing recommendations needs to be overcome
by adequate clinical trials to support PK/PD, efficacy
and safety. In addition, new data should be critically
reviewed and SPCs, together with internationally ac-
cepted guidelines, updated accordingly. The ultimate
goal for the paediatric community would be to have
evidence based dosing recommendations for the most
commonly used antibiotics and for these to be dissem-
inated effectively. Our study suggests a strategy to op-
timise antibiotic prescribing for European neonates.
Firstly, improved dissemination strategies are urgently
needed for antibiotics with clear evidence to support
a dosage regimen, e.g. aminoglycosides and cephalo-
sporins. Secondly, other antibiotics need an improved
evidence base that could be disseminated using the
knowledge translation strategies that have been applied for
aminoglycosides.
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